Back to Search
Start Over
A Longitudinal Analysis Reveals Early Activation and Late Alterations in B Cells During Primary HIV Infection in Mozambican Adults.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Jan 15; Vol. 11, pp. 614319. Date of Electronic Publication: 2021 Jan 15 (Print Publication: 2020). - Publication Year :
- 2021
-
Abstract
- Primary HIV infection (PHI) and subsequent chronic infection alter B-cell compartment. However, longitudinal analysis defining the dynamics of B-cell alterations are still limited. We longitudinally studied B-cell subsets in individuals followed for 1 year after PHI (n = 40). Treated and untreated chronic HIV infected (n = 56) and HIV-uninfected individuals (n = 58) were recruited as reference groups at the Manhiça District in Mozambique. B cells were analyzed by multicolor flow-cytometry. Anti-HIV humoral response and plasma cytokines were assessed by ELISA or Luminex-based technology. A generalized activation of B cells induced by HIV occurs early after infection and is characterized by increases in Activated and Tissue-like memory cells, decreases in IgM-IgD- (switched) and IgM-only B cells. These alterations remain mostly stable until chronic infection and are reverted in part by ART. In contrast, other parameters followed particular dynamics: PD-1 expression in memory cells decreases progressively during the first year of infection, Transitional B cells expand at month 3-4 after infection, and Marginal zone-like B cells show a late depletion. Plasmablasts expand 2 months after infection linked to plasma viral load and anti-p24 IgG3 responses. Most of well-defined changes induced by HIV in B-cell activation and memory subsets are readily observed after PHI, lasting until ART initiation. However, subsequent changes occur after sustained viral infection. These data indicate that HIV infection impacts B cells in several waves over time, and highlight that early treatment would result in beneficial effects on the B-cell compartment.<br />Competing Interests: Unrelated to this work, JB is CEO and founder of AlbaJuna Therapeutics, S.L. and JC is CSO and founder of AlbaJuna Therapeutics, S.L. The remaining authors declare that the research was conducted in the absence of any direct commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Jiménez, Pastor, Urrea, Rodríguez de la Concepción, Parker, Fuente-Soro, Jairoce, Mandomando, Carrillo, Naniche and Blanco.)
- Subjects :
- Adult
Anti-Retroviral Agents therapeutic use
B-Lymphocyte Subsets immunology
Chronic Disease
Cohort Studies
Cytokines blood
Flow Cytometry
HIV Infections drug therapy
HIV Infections pathology
HIV Infections virology
Humans
Immunity, Humoral
Immunoglobulin D immunology
Immunoglobulin G immunology
Immunoglobulin M immunology
Longitudinal Studies
Lymphocyte Activation
Mozambique epidemiology
Programmed Cell Death 1 Receptor metabolism
Prospective Studies
Viral Load
B-Lymphocytes immunology
HIV Infections immunology
HIV-1 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 33519823
- Full Text :
- https://doi.org/10.3389/fimmu.2020.614319